Pfizer Prevnar vaccine wins approval for ages 6-17
(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.
The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.
The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.
Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.
(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)
- Tweet this
- Share this
- Digg this
- Microsoft names next operating system 'Windows 10'
- Hong Kong protests approach potential National Day flashpoint
- Obama, Modi work to deepen improving U.S.-India ties
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State
- Tracy Morgan incredulous Wal-Mart blames him for accident injuries
Children represent just 15 percent of the recorded 3,091 Ebola deaths recorded mostly in Liberia, Sierra Leone and Guinea. But that number masks the broader impact the disease is having on children. Fear of contagion means many orphans, even those who test negative, are being abandoned. Full Article